Orbimed Advisors Reduces Terns Pharmaceuticals Stake Amid Shifting Clinical Developments in 2026 | MarketWire

Orbimed Advisors cut its Terns Pharmaceuticals stake after a strong year, raising questions about future clinical milestones.